Pyxis Oncology (PYXS)
(Delayed Data from NSDQ)
$3.75 USD
+0.52 (16.10%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $3.80 +0.05 (1.33%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.75 USD
+0.52 (16.10%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $3.80 +0.05 (1.33%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Zacks News
Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pyxis Oncology (PYXS) delivered earnings and revenue surprises of 77.78% and 279.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 61.3% in Pyxis Oncology (PYXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy
by Zacks Equity Research
Pyxis Oncology (PYXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)
by Zacks Equity Research
Pyxis Oncology, Inc. (PYXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Pyxis Oncology, Inc. (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pyxis (PYXS) Up on Advancing Cancer Therapy Candidates
by Zacks Equity Research
Pyxis' (PYXS) shares rise as the company advances its phase I candidates, PYX-106 and PYX-201, for challenging cancer therapies.
Apexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up
by Zacks Equity Research
Apexigen (APGN) surges as Pyxis Oncology offers to acquire it for approximately $16 million.
Is Clover Health Investments (CLOV) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Clover Health Investments, Corp. (CLOV) and Pyxis Oncology, Inc. (PYXS) have performed compared to their sector so far this year.